1,300 research outputs found
Group-II acceptors in wurtzite AlN: A screened hybrid density functional study
No full textWe systematically studied the group-II acceptors in wurtzite AlN by screened hybrid density functional calculations. We show that the shallowest isolated group-II substitutional defect is Mg, while codoping of Mg and O may yield even shallower acceptor level.Original Publication:Aron Szabo, Ngyen Tien Son, Erik Janzén and Adam Gali, Group-II acceptors in wurtzite AlN: A screened hybrid density functional study, 2010, APPLIED PHYSICS LETTERS, (96), 19, 192110.http://dx.doi.org/10.1063/1.3429086Copyright: American Institute of Physicshttp://www.aip.org
Accurate defect levels obtained from the HSE06 range-separated hybrid functional
No full textDefect levels are a problem for standard implementations of density-functional theory and the error also influences the energetics. We demonstrate that the HSE06 functional, which describes the electronic structure of all group-IV semiconductors well (including Ge), gives highly accurate charge transition levels, too, if the defect wave function is host related-independent of localization. The degree of fulfilling the generalized Koopmans theorem shows the reliability of the results and the highest-occupied eigenvalue always seems to give the correct vertical ionization energy.Original Publication:Peter Deak, Balint Aradi, Thomas Frauenheim, Erik Janzén and Adam Gali, Accurate defect levels obtained from the HSE06 range-separated hybrid functional, 2010, PHYSICAL REVIEW B, (81), 15, 153203.http://dx.doi.org/10.1103/PhysRevB.81.153203Copyright: American Physical Societyhttp://www.aps.org
Electronic and optical properties of pure and modified diamondoids studied by many-body perturbation theory and time-dependent density functional theory
No full textDiamondoids are small diamond nanoparticles (NPs) that are built up from diamond cages. Unlike usual semiconductor NPs, their atomic structure is exactly known, thus they are ideal test-beds for benchmarking quantum chemical calculations. Their usage in spintronics and bioimaging applications requires a detailed knowledge of their electronic structure and optical properties. In this paper, we apply density functional theory (DFT) based methods to understand the electronic and optical properties of a few selected pure and modified diamondoids for which accurate experimental data exist. In particular, we use many-body perturbation theory methods, in the G0W0 and G0W0+BSE approximations, and time-dependent DFT in the adiabatic local density approximation. We find large quasiparticle gap corrections that can exceed thrice the DFT gap. The electron-hole binding energy can be as large as 4 eV but it is considerably smaller than the GW corrections and thus G0W0+BSE optical gaps are about 50% larger than the Kohn-Sham (KS) DFT gaps. We find significant differences between KS time-dependent DFT and GW+BSE optical spectra on the selected diamondoids. The calculated G0W0 quasiparticle levels agree well with the corresponding experimental vertical ionization energies. We show that nuclei dynamics in the ionization process can be significant and its contribution may reach about 0.5 eV in the adiabatic ionization energies
Negyedik főcsoportbeli félvezető nanokristályok optikai tulajdonságainak atomi szintű számítógépes szimulációja
No full textRoom temperature Single Photon Sources in Silicon Carbide
No full textDefects are common in many materials and some were regarded for years as detrimental. Recently with the advent of ultra-sensitive detectors, quantum optical single spin magnetic resonance protocols and advanced material synthesis and doping, diamond intra-band gap defects and their nanostructured counterpart are revealed to be a disruptive discovery for the future of nanoscale sensing and quantum technologies[1]. We will report on recently studied optical centres in another wide-band gap semiconductor, such as silicon carbide (SiC). SiC harbors paramagnetic defects whose quantum properties were recently unraveled [2-7]. As occurred for similar diamond point defects[1], we have recently identified a bright single photon emission in 4H-SiC. We will show more recent results on single defects SiC nanoparticles [8], nanotetrapods [9] and other SiC quantum emission [10] providing novel information on their physics and atomistic structure. The fundamental understanding of these defects is essential for their engineering and deployment in next generation multifunctional sensors and in quantum nano- photonics.
We will discuss the potential designs of photonics cavities to further enhance some of these single photon sources
Ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Atminties vaidmuo formuojant tarptautinius santykius Vidurio Europoje
No full textPagrindinis tyrimo klausimas – ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Autorius teigia, kad, viena vertus, tiesos sąvokos atsisakymas istoriografijoje gali paskatinti istoriją traktuoti kaip selektyvių argumentų rezervuarą politinėse kovose. Šia prasme istorija visada skaldys. Kita vertus, tiesa gali būti pasiekta. Mokslininkai turi kelis būdus patikrinti, kiek toli nuo tiesos yra teiginys apie istoriją. Egzistuoja šešios pagrindinės tikrinimo taisyklės, kurios aptariamos straipsnyje. Nagrinėjama nacionalinio tapatumo samprata, kultūra, suvokiama kaip nacionalinio tapatumo pagrindas, ir regioninio bendradarbiavimo kontekstas.The main research question is whether history is doomed to divide or whether it may unite. The author argues that, on the one hand, the rejection of the concept of truth in historiography may lead to treating history as a reservoir of selective argument in political struggles. In this sense, history will always divide. However, on the other hand, truth may be achieved. Scholars have several ways to test how far from the truth is a statement concerning history. There are six basic rules to test it, which are discussed in the article. The concept of national identity, culture perceived as the backbone of national identity and the regional cooperation context are examined
Thymoquinone: Fifty years of success in the battle against cancer models
No full textThymoquinone (TQ), the main active constituent of black seed essential oil, exhibits promising effects against inflammatory diseases and cancer. TQ, modulates signaling pathways that are key to cancer progression, and enhances the anticancer potential of clinical drugs while reducing their toxic side effects. Considering that TQ was isolated 50 years ago, this review focuses on TQ's chemical and pharmacological properties and the latest advances in TQ analog design and nanoformulation. We discuss our current state of knowledge of TQ's adjuvant potential and in vivo antitumor activity and highlight its ability to modulate the hallmarks of cancer. © 2013 Elsevier Ltd. All rights reserved.Abusnina A, 2011, CELL SIGNAL, V23, P152, DOI 10.1016-j.cellsig.2010.08.015; Akhondian J, 2011, EPILEPSY RES, V93, P39, DOI 10.1016-j.eplepsyres.2010.10.010; Al-Ali Amein, 2008, J Ayub Med Coll Abbottabad, V20, P25; Alam S, 2012, INT J NANOMED, V7, P5705, DOI 10.2147-IJN.S35329; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Alenzi FQ, 2010, BRIT J BIOMED SCI, V67, P20; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007-s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016-j.bcp.2009.12.015; Al-Johar D, 2008, PHYTOTHER RES, V22, P1311, DOI 10.1002-ptr.2487; Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193; Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016-j.mrfmmm.2010.10.007; Badary OA, 2001, CANCER DETECT PREV, V25, P362; Badary OA, 1999, J ETHNOPHARMACOL, V67, P135, DOI 10.1016-S0378-8741(98)00242-6; Badary OA, 1999, EUR J CANCER PREV, V8, P435, DOI 10.1097-00008469-199910000-00009; Badary OA, 2000, TOXICOLOGY, V143, P219, DOI 10.1016-S0300-483X(99)00179-1; Badr G, 2011, PLOS ONE, V6, DOI 10.1371-journal.pone.0023741; Banerjee S, 2010, NUTR CANCER, V62, P938, DOI 10.1080-01635581.2010.509832; Banerjee S, 2010, PHARM RES-DORDR, V27, P1146, DOI 10.1007-s11095-010-0145-3; Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158-0008-5472.CAN-08-4235; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177-0960327111433185; Brewer J, 2006, BIOMED SCI INSTRUM, V42, P37; Chehl N, 2009, HPB, V11, P373, DOI 10.1111-j.1477-2574.2009.00059.x; CREMER D, 1987, J MED CHEM, V30, P1678, DOI 10.1021-jm00392a027; Daba MH, 1998, TOXICOL LETT, V95, P23, DOI 10.1016-S0378-4274(98)00012-5; Das S, 2012, PLOS ONE, V7, DOI 10.1371-journal.pone.0046641; Dergarabetian Eileen Manasse, 2013, Front Biosci (Elite Ed), V5, P706; Effenberger K, 2010, CHEM BIODIVERS, V7, P129, DOI 10.1002-cbdv.200900328; Effenberger-Neidnicht K, 2011, CHEMBIOCHEM, V12, P1237, DOI 10.1002-cbic.201000762; El-Dakhakhny M., 1963, PLANTA MED, V11, P465; El-Dakhakhny M, 2002, J ETHNOPHARMACOL, V81, P161, DOI 10.1016-S0378-8741(02)00051-X; El Gazzar MA, 2007, BBA-GEN SUBJECTS, V1770, P556, DOI 10.1016-j.bbagen.2007.01.002; El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002-ijc.21205; El Mezayen R, 2006, IMMUNOL LETT, V106, P72, DOI 10.1016-j.imlet.2006.04.012; El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007-s10495-009-0421-z; El-Najjar Nahed, 2011, J Chem Biol, V4, P97, DOI 10.1007-s12154-010-0052-4; Farah Nourelhoda, 2005, V41, P211; Fouda AMM, 2008, BASIC CLIN PHARMACOL, V103, P109, DOI 10.1111-j.1742-7843.2008.00260.x; Gali-Muhtasib H, 2008, J CELL MOL MED, V12, P330, DOI 10.1111-j.1582-4934.2007.00095.x; Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016-j.biocel.2005.10.009; Gali-Muhtasib H, 2008, CANCER RES, V68, P5609, DOI 10.1158-0008-5472.CAN-08-0884; Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097-01.cad.0000125054.43188.56; Ganea GM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088-0957-4484-21-28-285104; Gohari AR, 2012, SCI WORLD J, DOI 10.1100-2012-203861; Gokce A, 2011, HUM EXP TOXICOL, V30, P897, DOI 10.1177-0960327110382564; Grosso C, 2010, J SEP SCI, V33, P2211, DOI 10.1002-jssc.201000192; Gupta V.K., 2010, INT J RES PHARM SCI, V1, P163; Gurung R.L., 2010, PLOS ONE, V5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016-j.cell.2011.02.013; Harzallah HJ, 2012, OXID MED CELL LONGEV, DOI 10.1155-2012-854065; Hussain AR, 2011, FREE RADICAL BIO MED, V50, P978, DOI 10.1016-j.freeradbiomed.2010.12.034; Hussain J, 2010, NAT PROD COMMUN, V5, P1785; Ivankovic S., 2006, Experimental Oncology, V28, P220; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186-1756-9966-29-87; Kanter M, 2005, WORLD J GASTROENTERO, V11, P6662; Kanter M, 2008, NEUROCHEM RES, V33, P579, DOI 10.1007-s11064-007-9481-z; Kanter M, 2011, TOXICOL IND HEALTH, V27, P387, DOI 10.1177-0748233710387630; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158-0008-5472.CAN-07-1483; Koka PS, 2010, EXP BIOL MED, V235, P751, DOI 10.1258-ebm.2010.009369; Kolli-Bouhafs K, 2012, INVEST NEW DRUG, V30, P2121, DOI 10.1007-s10637-011-9777-3; Lei XF, 2012, DIGEST DIS SCI, V57, P2296, DOI 10.1007-s10620-012-2156-x; Li F, 2010, BRIT J PHARMACOL, V161, P541, DOI 10.1111-j.1476-5381.2010.00874.x; Lukas B, 2009, J AGR FOOD CHEM, V57, P1362, DOI 10.1021-jf802963h; Mansour MA, 2000, LIFE SCI, V66, P2583, DOI 10.1016-S0024-3205(00)00592-0; Manter DK, 2007, J CHEM ECOL, V33, P2133, DOI 10.1007-s10886-007-9368-0; Martin TM, 2006, BIOMED SCI INSTRUM, V42, P332; Mu Hai-qi, 2012, Zhonghua Yi Xue Za Zhi, V92, P392; Nagi MN, 2011, J BIOCHEM MOL TOXIC, V25, P135, DOI 10.1002-jbt.20369; Nagi MN, 2000, PHARMACOL RES, V41, P283, DOI 10.1006-phrs.1999.0585; Nagi MN, 2010, FOOD CHEM TOXICOL, V48, P2361, DOI 10.1016-j.fct.2010.05.072; Ng WK, 2011, TOXICOL IN VITRO, V25, P1392, DOI 10.1016-j.tiv.2011.04.030; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Norwood AA, 2006, BIOMED SCI INSTRUM, V42, P350; Odeh F, 2012, DRUG DELIV, V19, P371, DOI 10.3109-10717544.2012.727500; Paramasivam A, 2012, TOXICOL LETT, V213, P151, DOI 10.1016-j.toxlet.2012.06.011; Pathan SA, 2011, BIOMED CHROMATOGR, V25, P613, DOI 10.1002-bmc.1492; Ravindran J, 2010, BIOCHEM PHARMACOL, V79, P1640, DOI 10.1016-j.bcp.2010.01.023; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016-j.chembiol.2008.03.013; Richards LR, 2007, BIOMED SCI INSTRUM, V43, P242; Roepke M, 2007, CANCER BIOL THER, V6, P160; Rooney S, 2005, ANTICANCER RES, V25, P4255; Ross Richards L, 2009, BIOMED SCI INSTRUM, V45, P268; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016-j.intimp.2005.06.008; Sayed-Ahmed MM, 2007, CLIN EXP PHARMACOL P, V34, P399, DOI 10.1111-j.1440-1681.2007.04560.x; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158-1541-7786.MCR-07-2088; Shah M, 2010, INT J PHARMACEUT, V400, P165, DOI 10.1016-j.ijpharm.2010.08.008; Shah M, 2011, J NANOSCI NANOTECHNO, V11, P5702, DOI 10.1166-jnn.2011.4493; Singh A, 2013, COLLOID SURFACE B, V102, P822, DOI 10.1016-j.colsurfb.2012.08.038; Suddek GM, 2013, INFLAMMOPHARMACOLOGY, V21, P427, DOI 10.1007-s10787-012-0160-6; Sutton KM, 2012, BIOCHEM BIOPH RES CO, V426, P421, DOI 10.1016-j.bbrc.2012.08.111; Tan M, 2006, BIOMED SCI INSTRUM, V42, P363; Torres MP, 2010, MOL CANCER THER, V9, P1419, DOI 10.1158-1535-7163.MCT-10-0075; TRANG NTD, 1993, PLANTA MED, V59, P99, DOI 10.1055-s-2006-959619; Ulu R, 2012, FOOD CHEM TOXICOL, V50, P1675, DOI 10.1016-j.fct.2012.02.082; Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042-CBI20100701; Wang Yong-Mei, 2011, Zhonghua Yi Xue Za Zhi, V91, P3111; Wilson-Simpson F, 2007, BIOMED SCI INSTRUM, V43, P378; Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016-j.bcp.2011.05.030; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016-j.bcp.2011.09.029; Worthen DR, 1998, ANTICANCER RES, V18, P1527; Wu Zhi-hao, 2011, Yaoxue Xuebao, V46, P910; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158-1535-7163.MCT-08-0124; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021-cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016-j.ajpath.2011.06.031; Zafeer MF, 2012, J BIOCHEM MOL TOXIC, V26, P199, DOI 10.1002-jbt.2140268
Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development
No full textDrugs derived from natural products, particularly from plants, are the leads of clinically used anticancer agents. Plant-derived anticancer agents in clinical use consist of the Vinca alkaloids, vinblastine and vincristine, camptothecin derivatives, paclitaxel, etoposide and teniposide, homoharringtonine and elliptinium. Extensive research has led to the identification of promising plant-derived anticancer agents in clinical development, namely flavopiridol, combretastatins and roscovitine. These compounds share common antitumor activities and signaling pathways targeting tumor cell cycle and cell death. This review presents the discovery of plant-derived anticancer agents, their biologic activities, with emphasis on cell cycle and apoptotic effects and combination strategies for treatment optimization. © 2007 Informa UK Ltd.Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074-jbc.M005267200; Advani Ranjana, 2006, J Natl Compr Canc Netw, V4, P241; Aggarwal BB, 2004, EXPERT OPIN INV DRUG, V13, P1327, DOI 10.1517-13543784.13.10.1327; Albihn A, 2006, J CELL BIOCHEM, V98, P1597, DOI 10.1002-jcb.20816; Alonso M, 2003, MOL CANCER THER, V2, P139; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182-blood-2004-07-2713; ARMSTRON.JG, 1967, CANCER RES, V27, P221; Atanasova G, 2005, BIOCHEM PHARMACOL, V70, P824, DOI 10.1016-j.bcp.2005.06.005; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016-0003-9861(87)90463-2; BAASKE DM, 1977, ANTIMICROB AGENTS CH, V12, P298; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074-jbc.M500806200; Baldwin E. L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P363, DOI 10.2174-1568011054222364; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016-j.lfs.2005.09.012; Bennouna J, 2005, EXPERT OPIN INV DRUG, V14, P1259, DOI 10.1517-13543784.14.10.1259; Bergeron S, 2004, MOL CANCER THER, V3, P1659; Bhutani Manisha, 2006, Indian J Chest Dis Allied Sci, V48, P49; Blagosklonny Mikhail V, 2002, Cell Cycle, V1, P375; Blagosklonny MV, 2005, CELL CYCLE, V4, P269; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161-cc.3.12.1278; Borgne A, 2006, ONCOGENE, V25, P7361, DOI 10.1038-sj.onc.1209718; BROOKS DJ, 1996, SEMIN ONCOL S, V23, pS30; Cai Z, 2001, LEUKEMIA, V15, P567; Cai Z, 2005, CHINESE MED J-PEKING, V118, P548; Carlson BA, 1996, CANCER RES, V56, P2973; CASTOR TP, 2006, MASS HIGH TECH, V22, P1; Ceruti S, 2006, J PHARMACOL EXP THER, V319, P1424, DOI 10.1124-jpet.106.109397; Chang BD, 1999, CANCER RES, V59, P3761; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016-S1074-5521(99)80048-9; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074-jbc.M102306200; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016-j.canlet.2004.10.049; Ciusani E, 2005, J NEURO-ONCOL, V71, P19, DOI 10.1007-s11060-004-9180-4; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038-nature03194; Clegg A, 2001, Health Technol Assess, V5, P1; Conroy T, 2002, CRIT REV ONCOL HEMAT, V42, P173, DOI 10.1016-S1040-8428(01)00180-9; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016-j.jep.2005.05.011; Crescenzi E, 2005, CLIN CANCER RES, V11, P8158, DOI 10.1158-1078-0432; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016-S0140-6736(00)02074-2; Dark GG, 1997, CANCER RES, V57, P1829; Dasmahapatra G, 2006, MOL PHARMACOL, V69, P288, DOI 10.1124-mol.105.016154; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016-j.bcp.2006.02.015; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158-0008-5472.CAN-04-0204; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038-bjc.1982.16; Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038-nrd1382; Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174-1568011023354452; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158-0008-5472.CAN-04-4095; Etievant C, 2001, CANCER CHEMOTH PHARM, V48, P62, DOI 10.1007-s002800100275; Fan MY, 2000, CANCER RES, V60, P6403; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074-jbc.M411890200; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111-j.1432-1033.1977.tb11256.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998; Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016-j.ctrv.2006.07.001; Gali-Muhtasib H, 2002, CURR CANCER DRUG TAR, V2, P309, DOI 10.2174-1568009023333809; Garcia-Manero G, 2002, INTERNAL MED, V41, P254, DOI 10.2169-internalmedicine.41.254; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073-pnas.132275599; Giovannetti E, 2005, BRIT J CANCER, V92, P681, DOI 10.1038-sj.bjc.6602382; Glaberman Ursa, 2005, Expert Opin Drug Deliv, V2, P323, DOI 10.1517-17425247.2.2.323; Glaser T, 2001, BIOCHEM BIOPH RES CO, V281, P322, DOI 10.1006-bbrc.2001.4349; Gommersall LM, 2005, NAT CLIN PRACT ONCOL, V2, P298, DOI 10.1038-ncponc0196; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021-ja01517a031; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016-S1368-7646(02)00141-3; Greenberg VL, 2005, ONCOGENE, V24, P4851, DOI 10.1038-sj.onc.1208624; Grivicich I, 2005, ONCOL RES, V15, P385; Groninger E, 2002, INT J ONCOL, V21, P1339; Hagg M, 2004, MOL CANCER THER, V3, P489; Hartmann JT, 2006, DRUG SAFETY, V29, P209, DOI 10.2165-00002018-200629030-00005; Hartwell JL, 1982, PLANTS USED CANC; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038-sj.cgt.7700984; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038-sj-onc.1206409; Henfling MER, 2004, INT J ONCOL, V25, P1437; Henley D, 2007, CANCER CHEMOTH PHARM, V59, P235, DOI 10.1007-s00280-006-0262-1; Holwell SE, 2001, BRIT J CANCER, V84, P290, DOI 10.1054-bjoc.2000.1587; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; HUANG MT, 1975, MOL PHARMACOL, V11, P511; Islaih M, 2005, MUTAT RES-FUND MOL M, V578, P100, DOI 10.1016-j.mrfmmm.2005.04.012; Iyer S, 1998, CANCER RES, V58, P4510; Jean-Decoster C, 1999, ANTI-CANCER DRUG, V10, P537, DOI 10.1097-00001813-199907000-00005; Jin J, 2006, LEUKEMIA, V20, P1361, DOI 10.1038-sj.leu.2404287; JOHNSON IS, 1963, CANCER RES, V23, P1390; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174-1568011023354290; Kanthou C, 2004, AM J PATHOL, V165, P1401, DOI 10.1016-S0002-9440(10)63398-6; Karp JE, 2005, CLIN CANCER RES, V11, P8403, DOI 10.1158-1078-0432.CCR-05-1201; Karpinich NO, 2006, J CELL PHYSIOL, V208, P55, DOI 10.1002-jcp.20638; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093-jnci-84.22.1736; Kawakami K, 1999, ANTICANCER RES, V19, P3927; Kelland Lloyd R, 2005, Expert Opin Emerg Drugs, V10, P413, DOI 10.1517-14728214.10.2.413; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021-jm00105a017; Kitada S, 2000, BLOOD, V96, P393; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038-nrd1657; Koizumi N, 2005, INT J ONCOL, V26, P1301; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016-S0006-2952(01)00895-4; Kramer R, 2004, NAT REV DRUG DISCOV, V3, P965, DOI 10.1038-nrd1552; Kruczynski A, 1998, CANCER CHEMOTH PHARM, V41, P437, DOI 10.1007-s002800050764; Kumar L, 2006, NATL MED J INDIA, V19, P80; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016-j.canlet.2004.09.046; Kuo PL, 2005, ANTI-CANCER DRUG, V16, P789, DOI 10.1097-01.cad.0000171768.36317.93; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007-s10495-005-3372-z; LAVELLE F, 1995, SEMIN ONCOL S4, V22, pS3; Lee YK, 2006, MOL CANCER THER, V5, P138, DOI 10.1158-1535-7163.MCT-05-0235; Li QY, 2006, CURR MED CHEM, V13, P2021, DOI 10.2174-092986706777585004; Litz J, 2003, CLIN CANCER RES, V9, P4586; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054-bjoc.2001.2107; Lobert S, 1998, MOL PHARMACOL, V53, P908; LOGH BH, 1994, CANC CHEMOTHER PHA S, V34, pS26; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016-j.cccn.2005.02.003; Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016-j.orthres.2005.01.018; Luo Chang Ying, 2004, Hematology, V9, P259, DOI 10.1080-10245330410001714194; Lyseng-Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165-00003495-200565170-00007; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158-0008-5472.CAN-05-0233; Magalska A, 2006, INT J CANCER, V119, P1811, DOI 10.1002-ijc.22055; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021-ar0201198; Mialon A, 2005, MOL CELL BIOL, V25, P5040, DOI 10.1128-MCB.25.12.5040-5051.2005; Minderman H, 2005, MOL CANCER THER, V4, P885, DOI 10.1158-1535-7163.MCT-04-0048; Miyashita K, 2006, INT J MOL MED, V18, P249; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Navakauskiene R, 2004, ANN NY ACAD SCI, V1030, P393, DOI 10.1196-annals.1329.049; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093-jnci-83.16.1164; Newcomb EW, 2004, ANTI-CANCER DRUG, V15, P411, DOI 10.1097-01.cad.0000127332.06439.47; Newman DJ, 2002, CURR CANCER DRUG TAR, V2, P279, DOI 10.2174-1568009023333791; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021-np030096l; Ngan VK, 2000, CANCER RES, V60, P5045; NOBLE RL, 1958, ANN NY ACAD SCI, V76, P882, DOI 10.1111-j.1749-6632.1958.tb54906.x; Oberlies NH, 2004, J NAT PROD, V67, P129, DOI 10.1021-np030498t; O'Brien S, 2003, CANCER, V98, P888, DOI 10.1002-cncr.11620; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038-sj-cdd-4401012; OHASHI M, 1995, JPN J CANCER RES, V86, P819; Panno ML, 2006, FEBS LETT, V580, P2371, DOI 10.1016-j.febslet.2006.03.055; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074-jbc.M406543200; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038-sj.onc.1206777; Pepper Chris, 2003, Cell Cycle, V2, P53; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016-j.canlet.2005.01.018; Pettit GR, 1982, CAN J CHEM, V60, P1347; PETTIT GR, 1987, CAN J CHEM, V65, P2390; PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299; Podwyssotzki V, 1881, PHARM J T, V12, P217; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038-nrc1977; POTIER P, 1989, SEMIN ONCOL, V16, P2; Pourroy B, 2004, MOL PHARMACOL, V66, P580; POWELL RG, 1972, J PHARM SCI, V61, P1227, DOI 10.1002-jps.2600610812; Pratt MAC, 2006, APOPTOSIS, V11, P589, DOI 10.1007-s10495-006-4603-7; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128-MCB.20.8.2629-2634.2000; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182-blood-2005-01-0320; Ramnath N, 2005, CANCER CHEMOTH PHARM, V56, P447, DOI 10.1007-s00280-004-0951-6; Reck M, 2006, LUNG CANCER, V53, P67, DOI 10.1016-j.lungcan.2006.04.001; Reichert JM, 2003, NAT REV DRUG DISCOV, V2, P695, DOI 10.1038-nrd1178; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093-jnci-83.4.288; Rodriguez-Hernandez A, 2006, APOPTOSIS, V11, P131, DOI 10.1007-s10495-005-3276-y; Rossi A, 2003, ANTICANCER RES, V23, P1657; Rossi R, 2006, CANCER RES, V66, P1675, DOI 10.1158-0008-5472.CAN-05-2741; Russo AJ, 2006, CANCER RES, V66, P7253, DOI 10.1158-0008-5472.CAN-05-3725; Sambol EB, 2006, CANCER RES, V66, P5858, DOI 10.1158-0008-5472.CAN-05-2933; Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161-cc.5.18.3235; Scagliotti G, 2004, LUNG CANCER-J IASLC, V46, pS13, DOI 10.1016-S0169-5002(04)80037-0; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016-S1040-8428(00)00124-4; SENDEROWICZ AM, 2002, ONCOLOGIST S, V7, pS12; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038-sj.onc.1206954; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021-bi00200a007; Smith LM, 2005, CLIN CANCER RES, V11, P8449, DOI 10.1158-1078-0432.CCR-05-1224; Stiborova Marie, 2006, Biomedical Papers (Olomouc), V150, P13; Stiborova M, 2004, CANCER RES, V64, P8374, DOI 10.1158-0008-5472.CAN-04-2202; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158-0008-5472.CAN-05-1997; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016-S0014-2999(97)01520-3; Swanton C, 2006, CELL CYCLE, V5, P818, DOI 10.4161-cc.5.8.2682; Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158-1535-7163.MCT-04-0282; Tang RP, 2006, MOL CANCER THER, V5, P723, DOI 10.1158-1535-7163.MCT-05-0164; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158-0008-5472.CAN-03-2770; Taniguchi T, 2005, INT J MOL MED, V15, P667; Tirado OM, 2005, CANCER RES, V65, P9320, DOI 10.1158-0008-5472.CAN-05-1276; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038-nrc1628; Tron GC, 2006, J MED CHEM, V49, P3033, DOI 10.1021-jm0512903; Venkataraman G, 2006, LEUKEMIA RES, V30, P1377, DOI 10.1016-j.leukres.2006.03.004; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021-ja00968a057; Wall NR, 1999, LEUKEMIA RES, V23, P881, DOI 10.1016-S0145-2126(99)00108-3; Wall NR, 2003, CANCER RES, V63, P230; Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038-sj.onc.1207040; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074-jbc.274.12.8208; Wang Z, 2005, ANTICANCER RES, V25, P2367; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021-ja00738a045; Wehbe H, 2005, ANTICANCER RES, V25, P3865; Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113; West CML, 2004, ANTI-CANCER DRUG, V15, P179, DOI 10.1097-01.CAD.0000119456.84063.82; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158-0008-5472.CAN-03-0110; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016-0006-2952(93)90590-S; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158-1535-7163.MCT-06-0077; Xie WZ, 2006, AM J CHINESE MED, V34, P233, DOI 10.1142-S0192415X06003795; XU B, 1981, AM J CHINESE MED, V9, P268, DOI 10.1142-S0192415X81000354; Yinjun Lou, 2004, Am J Hematol, V76, P199, DOI 10.1002-ajh.20100; You YJ, 2005, CURR PHARM DESIGN, V11, P1695, DOI 10.2174-1381612053764724; Young SL, 2004, EXPERT OPIN INV DRUG, V13, P1171, DOI 10.1517-13543784.13.9.1171; Yu CR, 2003, CANCER RES, V63, P1822; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038-sj.onc.1209202; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174-1568009033333754; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038-sj.cgt.7700910; Zhao JS, 2005, INT J ONCOL, V27, P24756
Time-dependent density functional study on the excitation spectrum of point defects in semiconductors
No full textDefects in SiC: Theory
No full textA brief overview about the recent progress in developing the methods to calculate the properties of defects in solids is given and some recent examples on vacancy-related defects in SiC are presented.</jats:p
- …
